ArticleFrontiers in immunology2025
Influence of stage-specific and location-related intratumoral microbiota on prognosis and metabolic reprogramming in non-small cell lung cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung microbiota, gut microbiota, and the lung-gut axis in lung cancer immunotherapy: a tripartite regulatory perspective.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mounting evidence links intratumoral microbiota to tumor progression and immune regulation, but stage-specific and location-related microbial characteristics in NSCLC remain insufficiently explored. Methods: Tumor and adjacent non-tumor tissues from 21 NSCLC patients were analyzed using 16S rRNA gene sequencing to profile the intratumoral microbiota. Functional pathway analysis, in vitro co-culture experiments (A549/HCC827 cells), and in vivo mouse models were employed to validate microbial functions. Results: Microbial composition exhibited significant heterogeneity by tumor stage (early vs. advanced) and anatomical location (upper vs. lower lobes). Bacteroides was identified as a key genus enriched in early-stage tumors and correlated with improved prognosis. Functional analysis revealed enrichment of tumor-associated microbiota in metabolic and biosynthetic pathways (e.g., carbon metabolism, amino acid biosynthesis). Further experiments demonstrated that Bacteroides significantly suppressed NSCLC cell proliferation, inhibited migration, and promoted apoptosis, with anti-tumor effects mediated by remodeling the tumor immune microenvironment. Discussion: These findings elucidate intricate associations between intratumoral microbiota, immune cell infiltration, and patient prognosis, highlighting Bacteroides as a potential prognostic biomarker and therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.